About inotuzumab ozogamicin
CD22-targeted antibody–drug conjugate
Used for
- Treats adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.
Usual adult dose
Typically 1.8 mg/m² per treatment cycle, divided over three infusions; schedules and doses may change by cycle and response.
Common side effects
- Low blood-cell counts and infections
- Infusion reactions
- Liver injury, including sinusoidal obstruction syndrome
- Nausea, fever, fatigue, and bleeding
Important warnings
- Can cause severe, potentially fatal liver injury, especially around stem-cell transplantation.
- May cause prolonged low blood counts, serious infections, or bleeding.
- Infusion reactions can be severe; monitoring during and after infusion is required.
- Can harm an unborn baby; effective contraception is required during treatment and afterward.
Pregnancy
May cause fetal harm. Avoid pregnancy during treatment; follow the product information for contraception duration afterward.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least two months after the final dose.
Interactions
- Other medicines that prolong the QT interval may increase abnormal heart-rhythm risk.
- Medicines affecting liver enzymes or transporters may alter exposure; review all medicines with the oncology team.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.